trial · primary record
LY4257496
Breast Neoplasms
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 421 |
| Primary completion | 2035-04 |
| Primary endpoint | Phase 1a Dose Escalation: Maximum Tolerated Dose of LY4257496 |
| Registry ID | NCT07114601 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:30.917Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07114601
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.